DETECTNET: RadioMedix

Detectnet is a new isotope derived by RadioMedix for the positron imagining of the cancer. These is newly element approved by the FDA for identification. 

Detectnet consist of Cu64 dotatate injection these agent is used in PTE for the localization of somatostatin positive receptor in neuroendocrine tumor. The dosage of the detectent is being available at nuclear pharmacies. The phase III clinical trials shows the great result as a result these will be useful for the clinicians for guiding perfect dose for specific patient.